神经丝轻链蛋白在周围神经病中的应用价值探究

doi:10.12114/j.issn.1007-9572.2022.0571

中国全科医学 ›› 2022, Vol. 25 ›› Issue (32): 3977-3983.DOI: 10.12114/j.issn.1007-9572.2022.0571

所属专题：述评栏目最新文章合集

神经丝轻链蛋白在周围神经病中的应用价值探究

孙小玲¹, 黄凯伟¹, 万新贝¹, 吴莹¹, 李志军²^,^*()

1．430071　湖北省武汉市，湖北省直属机关医院内科
2．430030　湖北省武汉市，华中科技大学同济医学院附属同济医院神经内科

收稿日期:2022-05-30 修回日期:2022-07-30 出版日期:2022-11-15 发布日期:2022-08-04
通讯作者: 李志军
孙小玲，黄凯伟，万新贝，等.神经丝轻链蛋白在周围神经病中的应用价值探究[J].中国全科医学，2022，25（32）：3977-3983. [www.chinagp.net]
作者贡献：孙小玲、黄凯伟、万新贝、吴莹、李志军负责文献检索与整理；孙小玲负责论文起草与修订，对论文进行质量控制；李志军负责最终版本修订，对论文负责。
基金资助:
湖北省自然科学基金面上项目(2020CFB744); 湖北省卫生健康委员会科研项目(WJ2021M119)

Value of Neurofilament Light Chain as a Biomarker in Peripheral Neuropathy

SUN Xiaoling¹, HUANG Kaiwei¹, WAN Xinbei¹, WU Ying¹, LI Zhijun²^,^*()

1. Department of Internal Medicine, the Affiliated Hospital of Hubei Provincial Government, Wuhan 430071, China
2. Department of Neurology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China

Received:2022-05-30 Revised:2022-07-30 Published:2022-11-15 Online:2022-08-04
Contact: LI Zhijun
About author:
SUN X L, HUANG K W, WAN X B, et al. Value of neurofilament light chain as a biomarker in peripheral neuropathy [J]. Chinese General Practice, 2022, 25 (32) : 3977-3983.

分享到

摘要/Abstract

摘要： 神经丝轻链蛋白（NfL）已被确定为许多中枢神经系统疾病中轴突损伤的生物标志物，近年来关于NfL在周围神经病中的应用价值也逐渐引起关注。本研究回顾了血清NfL（sNfL）与各种免疫介导的周围神经病〔吉兰巴雷综合征（GBS）、慢性炎性脱髓鞘性神经根神经病（CIDP）等〕、遗传性周围神经病、药物相关性周围神经病、糖尿病周围神经病等轴突损伤的动态变化之间的关系，综合分析的结论为：sNfL定量可作为一个非常有潜力的生物标志物，监测疾病活动，评估疾病短期预后、长期预后，还可作为未来的临床试验和监测治疗反应的指标。

关键词: 周围神经系统疾病, 神经微丝蛋白质类, 神经丝轻链蛋白, 标记物, 临床, 中枢神经系统, 神经系统

Abstract:

Neurofilament light chain (NfL) has been identified as a biomarker of axonal injury in a variety of central nervous system diseases. The value of NfL as a biomarker in peripheral neuropathy has gained increasing attention. We reviewed the relationships of serum NfL with and the dynamics of axonal injury in various immune-mediated peripheral neuropathies (such as Guillain-Barre syndrome and chronic inflammatory demyelinating polyradiculoneuropathy), hereditary peripheral neuropathy, drug-induced peripheral neuropathies and diabetic peripheral neuropathy, and drew a conclusion after a comprehensive analysis: the quantified NfL may be used as a promising biomarker to monitor disease activity, assess short- and long-term prognosis, and also as a potential biomarker for clinical trials and monitoring treatment response.

Key words: Peripheral nervous system diseases, Neurofilament proteins, Neurofilament light protein, Markers, clinical, Central nervous system, Nervous system

孙小玲,黄凯伟,万新贝,等. 神经丝轻链蛋白在周围神经病中的应用价值探究[J]. 中国全科医学, 2022, 25(32): 3977-3983. DOI: 10.12114/j.issn.1007-9572.2022.0571.
SUN Xiaoling,HUANG Kaiwei,WAN Xinbei, et al. Value of Neurofilament Light Chain as a Biomarker in Peripheral Neuropathy[J]. Chinese General Practice, 2022, 25(32): 3977-3983. DOI: 10.12114/j.issn.1007-9572.2022.0571.

参考文献 51

[1]	KHALIL M，TEUNISSEN C E，OTTO M，et al. Neurofilaments as biomarkers in neurological disorders[J]. Nat Rev Neurol，2018，14（10）：577-589. DOI：10.1038/s41582-018-0058-z.
[2]	GAETANI L，BLENNOW K，CALABRESI P，et al. Neurofilament light chain as a biomarker in neurological disorders[J]. J Neurol Neurosurg Psychiatry，2019，90（8）：870-881. DOI：10.1136/jnnp-2018-320106.
[3]	BRIDEL C，VAN WIERINGEN W N，ZETTERBERG H，et al. Diagnostic value of cerebrospinal fluid neurofilament light protein in neurology: a systematic review and meta-analysis[J]. JAMA Neurol，2019，76（9）：1035-1048. DOI：10.1001/jamaneurol.2019.1534.
[4]	ZETTERBERG H. Neurofilament light: a dynamic cross-disease fluid biomarker for neurodegeneration[J]. Neuron，2016，91（1）：1-3. DOI：10.1016/j.neuron.2016.06.030.
[5]	PREISCHE O，SCHULTZ S A，APEL A，et al. Serum neurofilament dynamics predicts neurodegeneration and clinical progression in presymptomatic Alzheimer's disease[J]. Nat Med，2019，25（2）：277-283. DOI：10.1038/s41591-018-0304-3.
[6]	ASHTON N J，LEUZY A，LIM Y M，et al. Increased plasma neurofilament light chain concentration correlates with severity of post-mortem neurofibrillary tangle pathology and neurodegeneration[J]. Acta Neuropathol Commun，2019，7（1）：5. DOI：10.1186/s40478-018-0649-3.
[7]	HÅKANSSON I，TISELL A，CASSEL P，et al. Neurofilament levels，disease activity and brain volume during follow-up in multiple sclerosis[J]. J Neuroinflammation，2018，15（1）：209. DOI：10.1186/s12974-018-1249-7.
[8]	DEISENHAMMER F，ZETTERBERG H，FITZNER B，et al. The cerebrospinal fluid in multiple sclerosis[J]. Front Immunol，2019，10: 726. DOI：10.3389/fimmu.2019.00726.
[9]	KAPOOR R，SMITH K E，ALLEGRETTA M，et al. Serum neurofilament light as a biomarker in progressive multiple sclerosis[J]. Neurology，2020，95（10）：436-444. DOI：10.1212/WNL.0000000000010346.
[10]	MOMTAZMANESH S，SHOBEIRI P，SAGHAZADEH A，et al. Neuronal and glial CSF biomarkers in multiple sclerosis: a systematic review and meta-analysis[J]. Rev Neurosci，2021，32（6）：573-595. DOI：10.1515/revneuro-2020-0145.
[11]	FERREIRA-ATUESTA C，REYES S，GIOVANONNI G，et al. The evolution of neurofilament light chain in multiple sclerosis[J]. Front Neurosci，2021，15: 642384. DOI：10.3389/fnins.2021.642384.
[12]	SHAHIM P，TEGNER Y，MARKLUND N，et al. Neurofilament light and tau as blood biomarkers for sports-related concussion[J]. Neurology，2018，90（20）：e1780-1788. DOI：10.1212/WNL.0000000000005518.
[13]	THOMPSON A G B，LUK C，HESLEGRAVE A J，et al. Neurofilament light chain and tau concentrations are markedly increased in the serum of patients with sporadic Creutzfeldt-Jakob disease，and tau correlates with rate of disease progression[J]. J Neurol Neurosurg Psychiatry，2018，89（9）：955-961. DOI：10.1136/jnnp-2017-317793.
[14]	JOHNSON E B，BYRNE L M，GREGORY S，et al. Neurofilament light protein in blood predicts regional atrophy in Huntington disease[J]. Neurology，2018，90（8）：e717-723. DOI：10.1212/WNL.0000000000005005.
[15]	EVERS K S，ATKINSON A，BARRO C，et al. Neurofilament as neuronal injury blood marker in preeclampsia[J]. Hypertension，2018，71（6）：1178-1184. DOI：10.1161/HYPERTENSIONAHA.117.10314.
[16]	GAETANI L，BLENNOW K，CALABRESI P，et al. Neurofilament light chain as a biomarker in neurological disorders[J]. J Neurol Neurosurg Psychiatry，2019，90（8）：870-881. DOI：10.1136/jnnp-2018-320106.
[17]	LEE Y C，LEE B H，YIP W，et al. Neurofilament proteins as prognostic biomarkers in neurological disorders[J]. Curr Pharm Des，2020，25（43）：4560-4569. DOI：10.2174/1381612825666191210154535.
[18]	BRIDEL C，VAN WIERINGEN W N，ZETTERBERG H，et al. Diagnostic value of cerebrospinal fluid neurofilament light protein in neurology: a systematic review and meta-analysis[J]. JAMA Neurol，2019，76（9）：1035-1048. DOI：10.1001/jamaneurol.2019.1534.
[19]	AXELSSON M，SJÖGREN M，ANDERSEN O，et al. Neurofilament light protein levels in cerebrospinal fluid predict long-term disability of Guillain-Barré syndrome: a pilot study[J]. Acta Neurol Scand，2018，138（2）：143-150. DOI：10.1111/ane.12927.
[20]	KUHLE J，BARRO C，ANDREASSON U，et al. Comparison of three analytical platforms for quantification of the neurofilament light chain in blood samples: ELISA，electrochemiluminescence immunoassay and Simoa[J]. Clin Chem Lab Med，2016，54（10）：1655-1661. DOI：10.1515/cclm-2015-1195.
[21]	ALTMANN P，DE SIMONI D，KAIDER A，et al. Increased serum neurofilament light chain concentration indicates poor outcome in Guillain-Barré syndrome[J]. J Neuroinflammation，2020，17（1）：86. DOI：10.1186/s12974-020-01737-0.
[22]	MARTÍN-AGUILAR L，CAMPS-RENOM P，LLEIXÀ C，et al. Serum neurofilament light chain predicts long-term prognosis in Guillain-Barré syndrome patients[J]. J Neurol Neurosurg Psychiatry，2020：2020. DOI：10.1136/jnnp-2020-323899.
[23]	MATTSSON N，CULLEN N C，ANDREASSON U，et al. Association between longitudinal plasma neurofilament light and neurodegeneration in patients with alzheimer disease[J]. JAMA Neurol，2019，76（7）：791-799. DOI：10.1001/jamaneurol.2019.0765.
[24]	VAGBERG M，NORGREN N，DRING A，et al. Levels and age dependency of neurofilament light and glial fibrillary acidic protein in healthy individuals and their relation to the brain parenchymal fraction[J]. PLoS One，2015，10（8）：e0135886. DOI：10.1371/journal.pone.0135886.
[25]	KHALIL M，PIRPAMER L，HOFER E，et al. Serum neurofilament light levels in normal aging and their association with morphologic brain changes[J]. Nat Commun，2020，11（1）：812. DOI：10.1038/s41467-020-14612-6.
[26]	MILLERE E，ROTS D，SIMRÉN J，et al. Plasma neurofilament light chain as a potential biomarker in Charcot-Marie-Tooth disease[J]. Eur J Neurol，2021，28（3）：974-981. DOI：10.1111/ene.14689.
[27]	WILLISON H J，JACOBS B C，VAN DOORN P A. Guillain-Barré syndrome[J]. Lancet，2016，388（10045）：717-727. DOI：10.1016/S0140-6736(16)00339-1.
[28]	MARIOTTO S，FARINAZZO A，MAGLIOZZI R，et al. Serum and cerebrospinal neurofilament light chain levels in patients with acquired peripheral neuropathies[J]. J Peripher Nerv Syst，2018，23（3）：174-177. DOI：10.1111/jns.12279.
[29]	GAIOTTINO J，NORGREN N，DOBSON R，et al. Increased neurofilament light chain blood levels in neurodegenerative neurological diseases[J]. PLoS One，2013，8（9）：e75091. DOI：10.1371/journal.pone.0075091.
[30]	KÖRTVELYESSY P，KUHLE J，DÜZEL E，et al. Ratio and index of Neurofilament light chain indicate its origin in Guillain-Barré Syndrome[J]. Ann Clin Transl Neurol，2020，7（11）：2213-2220. DOI：10.1002/acn3.51207.
[31]	MARIOTTO S，CARTA S，BOZZETTI S，et al. Sural nerve biopsy: current role and comparison with serum neurofilament light chain levels[J]. J Neurol，2020，267（10）：2881-2887. DOI：10.1007/s00415-020-09949-3.
[32]	LEHMANN H C，BURKE D，KUWABARA S. Chronic inflammatory demyelinating polyneuropathy: update on diagnosis，immunopathogenesis and treatment[J]. J Neurol Neurosurg Psychiatry，2019，90（9）：981-987. DOI：10.1136/jnnp-2019-320314.
[33]	VAN DEN BERGH P Y K，VAN DOORN P A，HADDEN R D M，et al. European Academy of Neurology/Peripheral Nerve Society guideline on diagnosis and treatment of chronic inflammatory demyelinating polyradiculoneuropathy: report of a joint Task Force-Second revision[J]. Eur J Neurol，2021，28（11）：3556-3583. DOI：10.1111/ene.14959.
[34]	STASCHEIT F，HOTTER B，KLOSE S，et al. Calprotectin in chronic inflammatory demyelinating polyneuropathy and variants-a potential novel biomarker of disease activity[J]. Front Neurol，2021，12: 723009. DOI：10.3389/fneur.2021.723009.
[35]	FUKAMI Y，IIJIMA M，KOIKE H，et al. Association of serum neurofilament light chain levels with clinicopathology of chronic inflammatory demyelinating polyneuropathy，including NF155 reactive patients[J]. J Neurol，2021，268（10）：3835-3844. DOI：10.1007/s00415-021-10537-2.
[36]	VAN LIEVERLOO G G A，WIESKE L，VERHAMME C，et al. Serum neurofilament light chain in chronic inflammatory demyelinating polyneuropathy[J]. J Peripher Nerv Syst，2019，24（2）：187-194. DOI：10.1111/jns.12319.
[37]	HAYASHI T，NUKUI T，PIAO J L，et al. Serum neurofilament light chain in chronic inflammatory demyelinating polyneuropathy[J]. Brain Behav，2021，11（5）：e02084. DOI：10.1002/brb3.2084.
[38]	GODELAINE J，DE SCHAEPDRYVER M，BOSSUYT X，et al. Prognostic value of neurofilament light chain in chronic inflammatory demyelinating polyneuropathy[J]. Brain Commun，2021，3（1）：fcab018. DOI：10.1093/braincomms/fcab018.
[39]	KOIKE H，KATSUNO M. Pathophysiology of chronic inflammatory demyelinating polyneuropathy: insights into classification and therapeutic strategy[J]. Neurol Ther，2020，9（2）：213-227. DOI：10.1007/s40120-020-00190-8.
[40]	AMAADOR K，WIESKE L，KOEL-SIMMELINK M J A，et al. Serum neurofilament light chain，contactin-1 and complement activation in anti-MAG IgM paraprotein-related peripheral neuropathy[J]. J Neurol，2022，269（7）：3700-3705. DOI：10.1007/s00415-022-10993-4.
[41]	BISCHOF A，MANIGOLD T，BARRO C，et al. Serum neurofilament light chain: a biomarker of neuronal injury in vasculitic neuropathy[J]. Ann Rheum Dis，2018，77（7）：1093-1094. DOI：10.1136/annrheumdis-2017-212045.
[42]	SANDELIUS Å，ZETTERBERG H，BLENNOW K，et al. Plasma neurofilament light chain concentration in the inherited peripheral neuropathies[J]. Neurology，2018，90（6）：e518-524. DOI：10.1212/WNL.0000000000004932.
[43]	MAIA L F，MACESKI A，CONCEIÇÃO I，et al. Plasma neurofilament light chain: an early biomarker for hereditary ATTR amyloid polyneuropathy[J]. Amyloid，2020，27（2）：97-102. DOI：10.1080/13506129.2019.1708716.
[44]	LOUWSMA J，BRUNGER A F，BIJZET J，et al. Neurofilament light chain，a biomarker for polyneuropathy in systemic amyloidosis[J]. Amyloid，2021，28（1）：50-55. DOI：10.1080/13506129.2020.1815696.
[45]	LUIGETTI M，DI PAOLANTONIO A，GUGLIELMINO V，et al. Neurofilament light chain as a disease severity biomarker in ATTRv: data from a single-centre experience[J]. Neurol Sci，2022，43（4）：2845-2848. DOI：10.1007/s10072-021-05850-7.
[46]	MEREGALLI C，FUMAGALLI G，ALBERTI P，et al. Neurofilament light chain as disease biomarker in a rodent model of chemotherapy induced peripheral neuropathy[J]. Exp Neurol，2018，307: 129-132. DOI：10.1016/j.expneurol.2018.06.005.
[47]	MEREGALLI C，FUMAGALLI G，ALBERTI P，et al. Neurofilament light chain: a specific serum biomarker of axonal damage severity in rat models of Chemotherapy-Induced Peripheral Neurotoxicity[J]. Arch Toxicol，2020，94（7）：2517-2522. DOI：10.1007/s00204-020-02755-w.
[48]	KIM S H，CHOI M K，PARK N Y，et al. Serum neurofilament light chain levels as a biomarker of neuroaxonal injury and severity of oxaliplatin-induced peripheral neuropathy[J]. Sci Rep，2020，10（1）：7995. DOI：10.1038/s41598-020-64511-5.
[49]	HUEHNCHEN P，SCHINKE C，BANGEMANN N，et al. Neurofilament proteins as a potential biomarker in chemotherapy-induced polyneuropathy[J]. JCI Insight，2022，7（6）：e154395. DOI：10.1172/jci.insight.154395.
[50]	CELIKBILEK A，TANIK N，SABAH S，et al. Elevated neurofilament light chain （NFL） mRNA levels in prediabetic peripheral neuropathy[J]. Mol Biol Rep，2014，41（6）：4017-4022. DOI：10.1007/s11033-014-3270-y.
[51]	MORGENSTERN J，GROENER J B，JENDE J M E，et al. Neuron-specific biomarkers predict hypo- and hyperalgesia in individuals with diabetic peripheral neuropathy[J]. Diabetologia，2021，64（12）：2843-2855. DOI：10.1007/s00125-021-05557-6.

神经丝轻链蛋白在周围神经病中的应用价值探究

Value of Neurofilament Light Chain as a Biomarker in Peripheral Neuropathy

RichHTML

PDF

PDF (英文版)

可视化

摘要/Abstract

引用本文

使用本文

参考文献 51

相关文章 15

编辑推荐

Metrics

留言

[1]	张含之, 葛许华, 陆媛, 金花, 郭爱珍, 陈宇革, 马琳琳, 潘莹, 于德华. 基于岗位胜任力的全科医生临床诊疗思维能力继续教育培养探索及差异化分析[J]. 中国全科医学, 2023, 26(34): 4315-4321.
[2]	李殿江, 潘恩春, 孙中明, 文进博, 王苗苗, 武鸣, 沈冲. 社区2型糖尿病患者临床惰性现状及其影响因素分析[J]. 中国全科医学, 2023, 26(34): 4296-4301.
[3]	梁譞, 那飞扬, 秦梦瑶, 杨辉, 郭丽, 郭琪, 任蕾, 陈德, 刘东海, 张蓉芳. 儿童支气管哮喘合并阻塞性睡眠呼吸暂停低通气综合征的临床特征及影响因素研究[J]. 中国全科医学, 2023, 26(33): 4225-4230.
[4]	周英达, 卓书雄, 杨郗, 金花, 于德华. 社区全科未分化疾病临床路径的实施现状及构建策略研究[J]. 中国全科医学, 2023, 26(31): 3939-3944.
[5]	郑玉玲, 张亚玲, 刘怀民, 许彦超, 贾晓琳, 李军赛, 贺文龙, 仝新朵, 秦善文, 张丽涵. 丁香管食通含化丸单用及联合附桂管食通颗粒治疗晚期食管癌的临床研究[J]. 中国全科医学, 2023, 26(30): 3765-3771.
[6]	黄泰帅, 池艳, 何萍, 黄国兰, 左延莉. 基于倾向性评分匹配法探究拮抗剂方案与短效长方案在鲜胚移植中应用的成本-效果分析[J]. 中国全科医学, 2023, 26(30): 3809-3814.
[7]	中国医药教育协会眩晕专业委员会. 甲磺酸倍他司汀治疗眩晕症的专家共识[J]. 中国全科医学, 2023, 26(29): 3591-3598.
[8]	周文京, 赏石丽, 杨倩, 冯悦荣, 李俊. 血小板/白蛋白比值与免疫球蛋白A肾病临床和病理特征的相关性研究[J]. 中国全科医学, 2023, 26(29): 3657-3664.
[9]	牛国辉, 李停停, 朱登纳, 王军, 刘红星, 王鑫, 张萌萌, 谢加阳. 不同性别儿童全面性发育迟缓的临床特征研究[J]. 中国全科医学, 2023, 26(26): 3276-3281.
[10]	赵丽珍, 李卫民, 姜瑞霞. 系统免疫炎症指数对社区老年2型糖尿病患者并发糖尿病肾病的临床诊断价值研究[J]. 中国全科医学, 2023, 26(18): 2227-2231.
[11]	陈璐璐, 张利苹, 李静文, 董文杰, 吴欣爱. 程序性死亡受体1抑制剂联合呋喹替尼后线治疗转移性结直肠癌的临床疗效和安全性研究[J]. 中国全科医学, 2023, 26(18): 2262-2267.
[12]	王欣, 赵瑞斌, 杨花芳, 刘崇, 刘甜, 路翠, 陈迪迪. 儿童抗髓鞘少突胶质细胞糖蛋白免疫球蛋白G抗体相关疾病的表型特征及复发因素研究[J]. 中国全科医学, 2023, 26(18): 2244-2249.
[13]	杨玉丽, 井明霞, 胡欣, 杨萍, 闫小龙. 基于宫颈癌前病变患者的癌症治疗功能评价系统-共性模块量表最小临床重要性差值的影响因素研究[J]. 中国全科医学, 2023, 26(17): 2108-2113,2119.
[14]	薛婧如, 孙素真. 儿童肺炎支原体脑炎的临床特征及预后不良危险因素分析[J]. 中国全科医学, 2023, 26(17): 2125-2131.
[15]	中国老年护理联盟, 中南大学湘雅护理学院（中南大学湘雅泛海健康管理研究院）, 中南大学湘雅医院（国家老年疾病临床医学研究中心）, 北京医院（国家老年医学中心、国家老年疾病临床医学研究中心）, 李孟琦, 伍丽娜, 宁红婷, 冯辉. 营养不良老年人非药物干预临床实践指南[J]. 中国全科医学, 2023, 26(17): 2055-2069.